Hun Ju Lee, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO2020
5:08
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
Lymphoma Similar Videos
-
IUCLS 2023 Saturday Morning General Session_Sonali Smith, MD, FASCO_Andrew Evens, DO, MBA, MSc_Timothy Fenske, MD, MS
8:39
-
IUCLS 2023 Saturday Afternoon General Session_Sonali Smith, MD, FASCO_Andrew Evens, DO, MBA, MSc_Timothy Fenske, MD, MS
3:34
-
Virtual Challenging Case Clinic: B-cell Lymphomas - Chronic Lymphocytic Leukemia_Jennifer Brown, MD, PhD
49:09